Cancer Research Technology links with Celgene
Cancer Research UK’s subsidiary Cancer Research Technology (CRT) has signed a five-year drug-discovery deal with Celgene to develop and commercialise new anti-cancer treatments.
Read More
Tag: CRT
CR UK trials early-stage Lilly drug
Cancer Research UK has launched a new multi-site trial of an early-stage experimental therapy owned by Eli Lilly assessing its potential in a range of advanced cancers.
Read More
CRUK brings commercialisation arm in-house
Cancer Research UK has brought its commercialisation arm, Cancer Research Technology (CRT), together with its research funding teams to form a new in-house division called Research and Innovation.
Read More
CRT expands drug discovery deal with Merck
Cancer Research Technology is extending its deal with Germany’s Merck to discover new cancer drugs targeting the Hippo signalling pathway, which regulates cell proliferation and apoptosis to control tissue growth.
Read More
UK trial for new bladder cancer therapy
An experimental therapy for bladder cancer in on the brink of entering Phase I clinical trials in the UK after a development pact was signed between Cancer Research UK, its commercial arm Cancer Research Technology, and Canadian biotech Sitka Biopharma.
Read More
CR UK, HitGen work together on new lung cancer medicines
Cancer Research UK, its commercial arm Cancer Research Technology (CRT) and private biotech HitGen have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Read More
CRT, Tusk and UCL form immuno-oncology pact
Cancer Research Technology, Tusk Therapeutics and UCL (University College London) have have signed a pact to research, develop and commercialise an antibody-based therapeutic against a target known to play a key role in immune suppression in cancer.
Read More
Bicycle, CR UK work together on new cancer drugs
Cancer Research UK, Cancer Research Technology (CRT) and UK biotech Bicycle Therapeutics have formed a pact to trial a first-in-class experimental drug for cancers of high unmet need.
Read More
CRT Pioneer Fund invests in BCL6 project
The Cancer Research Technology Pioneer Fund is making its ninth investment in a project aiming to develop a new class of therapies for patients with diffuse large B-cell lymphoma – a sub-type of Non-Hodgkin Lymphoma (NHL).
Read More
CRT picks up ‘success payment’ from GSK
GlaxoSmithKline has issued an undisclosed ‘success payment’ to Cancer Research Technology relating to a collaboration developing molecules targeting cancer epigenetics – the way cells control how and when genes are turned on or off.
Read More
Syncona, CRT create new company Achilles
Syncona and Cancer Research Technology have announced the launch of a new private company – Achilles Therapeutics – that will bring together research from University College London and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research.
Read More
Imperial Innovations streams £5.1m into new biotech Artios
Imperial Innovations is streaming £5.1 million into newborn biotech Artios Pharma, giving the firm a 14.9 percent stake in its business.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
